GLP-1 Drugs Improve Nerve Function in Diabetic Neuropathy — Previously Thought Irreversible | Research

The takeaway

GLP-1 receptor agonists improved clinical neuropathy scores and nerve conduction in 24 diabetic neuropathy patients after just 3 months, potentially reversing what was considered irreversible nerve damage.

Neuropathy scores improved: 3.7→2.3 (p=0.005)
After just 3 months of GLP-1 receptor agonist therapy in diabetic peripheral neuropathy — a condition previously considered relentlessly progressive and irreversible

What the researchers found

Twenty-four participants with diabetic peripheral neuropathy treated with GLP-1 receptor agonists showed significant improvement in clinical neuropathy scores (TNS improved from 3.7 to 2.3, p=0.005) and nerve conduction (sural nerve amplitude improved from 11.9 to 14.2 μV, p=0.013) after 3 months. Axonal excitability testing revealed improvements consistent with enhanced Na+/K+-ATPase pump function and Na+ permeability, supported by mathematical modeling. Three GLP-1RAs were used: semaglutide, dulaglutide, and exenatide.

Why it matters

Diabetic peripheral neuropathy has been considered 'relentlessly progressive and irreversible' — there are no approved disease-modifying treatments. The finding that GLP-1 receptor agonists can improve nerve function in just 3 months is potentially paradigm-shifting. Since millions of people are already taking these drugs for diabetes and obesity, this represents a major potential bonus benefit for a devastating complication that currently has no effective treatment.

The numbers in context

n=24 · 3-month follow-up · TNS improved: 3.7→2.3 (p=0.005) · Sural amplitude: 11.9→14.2 μV (p=0.013) · Improved Na+/K+-ATPase pump function · 3 GLP-1RAs: semaglutide, dulaglutide, exenatide

How the study worked

Prospective observational study. Fourteen participants newly prescribed semaglutide or dulaglutide for type 2 diabetes underwent clinical assessment, nerve conduction studies, and axonal excitability testing at baseline and 3 months. These data were combined with 10 participants previously studied on exenatide therapy (total n=24). Mathematical modeling of axonal excitability data was performed to identify mechanisms of improvement.

Who was studied

24 participants with type 2 diabetes and diabetic peripheral neuropathy treated with GLP-1 receptor agonists (semaglutide, dulaglutide, or exenatide)

What this study cannot tell us

This is a small, open-label observational study (n=24) without a control group or randomization. Improvements could partly reflect better glycemic control rather than direct neuroprotective effects. The 3-month follow-up is short — longer studies are needed to determine if benefits are sustained. Combining data from three different GLP-1RAs and two separate cohorts introduces heterogeneity.

How to read the evidence

This is a prospective observational study without randomization or a control group, with a small sample size of 24 participants. While the neurophysiological improvements are objectively measured and the mechanism is supported by mathematical modeling, larger randomized controlled trials are needed to confirm causation.

When this study was published

Published in 2025, this is among the first prospective studies to demonstrate neurophysiological improvements with GLP-1 receptor agonists in diabetic neuropathy. The field is rapidly developing as the neuroprotective potential of these drugs attracts increasing research attention.

The bigger picture

This study adds to the growing evidence that GLP-1 receptor agonists have benefits far beyond blood sugar and weight control. GLP-1 receptors have been identified in the peripheral nervous system, suggesting direct neuroprotective effects independent of glycemic control. If confirmed in larger trials, this could fundamentally change how we treat diabetic neuropathy — from managing symptoms to actually reversing nerve damage — using drugs that are already widely prescribed.

Questions still open

Are the nerve function improvements driven by direct GLP-1 receptor activation in peripheral nerves, or primarily by improved glycemic control?
Do the improvements persist beyond 3 months, and is there a dose-response relationship across different GLP-1 receptor agonists?
Would a randomized controlled trial with an active comparator (e.g., insulin achieving similar glycemic control) confirm a neuroprotective effect independent of glucose lowering?

Common questions

What is diabetic peripheral neuropathy and why is it considered irreversible?

Diabetic peripheral neuropathy is nerve damage caused by chronically high blood sugar that affects the hands and feet, causing numbness, tingling, pain, and weakness. It has been considered irreversible because once nerve fibers are damaged by prolonged glucose toxicity, they typically don't recover — no medications have been approved to reverse the damage, only to manage symptoms like pain.

How might GLP-1 drugs actually repair damaged nerves?

This study found that GLP-1 receptor agonists improved the function of Na+/K+-ATPase pumps in nerve fibers — these pumps are essential for generating electrical signals along nerves and are impaired in diabetes. GLP-1 receptors exist on peripheral nerves, suggesting the drugs may directly stimulate nerve repair mechanisms, not just help nerves indirectly through better blood sugar control.

Read the original research

Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.

Journal of neurophysiology, 133(1), 14-21

View on PubMed ↗Publisher’s paper ↗

Citation

Dhanapalaratnam, Roshan; Issar, Tushar; Poynten, Ann M; Milner, Kerry-Lee; Kwai, Natalie C G; Krishnan, Arun V. (2025). Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.. Journal of neurophysiology, 133(1), 14-21. https://doi.org/10.1152/jn.00228.2024